Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Blood Transfus ; 15(5): 472-477, 2017 Sep.
Article in English | MEDLINE | ID: mdl-27416573

ABSTRACT

BACKGROUND: The incidence of alloimmunisation in myelodysplastic syndromes (MDS) during the era of supportive treatment ranges from 9 to 56%. However, it is unknown if the widespread use of hypomethylating agents has changed the risk of immunisation. The aim of this study is to evaluate the impact of azacitidine (AZA) therapy on red blood cell (RBC) alloimmunisation in transfused patients with MDS, myelodysplastic syndromes/myeloproliferative syndromes (MDS/MPS) and secondary acute myeloid leukaemia (AML). MATERIAL AND METHODS: We have analysed retrospectively all patients with MDS, MDS/MPS and secondary AML from MDS, who received their first transfusion in our hospital between January 1995 and December 2014. We have assessed the impact of age, sex, RBC and platelets units transfused, and AZA treatment on developing alloantibodies. RESULTS: In our study, the number of RBC units transfused increased the risk of developing alloantibodies. However aging and the treatment with AZA were associated with a lower rate of alloimmunisation. DISCUSSION: Patients with MDS, MDS/MPS and secondary AML who received treatment with AZA developed RBC antibodies at a lower rate than control group. We suggest that aging and immunosuppression due to AZA therapy could develop an immunological tolerance with a weak response to allotransfusions.


Subject(s)
Autoantibodies/immunology , Azacitidine/adverse effects , Erythrocyte Transfusion/adverse effects , Erythrocytes/immunology , Myelodysplastic Syndromes , Transfusion Reaction/immunology , Adult , Aged , Aged, 80 and over , Azacitidine/administration & dosage , Erythrocytes/pathology , Female , Humans , Immunization , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/pathology , Myelodysplastic Syndromes/therapy , Transfusion Reaction/chemically induced , Transfusion Reaction/pathology
2.
Transfusion ; 55 Suppl 2: S47-58, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26174897

ABSTRACT

BACKGROUND: The clinical consequences of antibodies to red blood cells (RBCs) have been studied for a century. Most clinically relevant antibodies can be detected by sensitive in vitro assays. Several mechanisms of antibody-mediated hemolysis are well understood. Such hemolysis after transfusion is reliably avoided in a donor-recipient pair, if one individual is negative for the cognate antigen to which the other has the antibody. STUDY DESIGN AND RESULTS: Mechanisms of antibody-mediated hemolysis were reviewed based on a presentation at the Strategies to Address Hemolytic Complications of Immune Globulin Infusions Workshop addressing intravenous immunoglobulin (IVIG) and ABO antibodies. The presented topics included the rates of intravascular and extravascular hemolysis; immunoglobulin (Ig)M and IgG isoagglutinins; auto- and alloantibodies; antibody specificity; A, B, A,B, and A1 antigens; A1 versus A2 phenotypes; monocytes-macrophages, other immune cells, and complement; monocyte monolayer assay; antibody-dependent cell-mediated cytotoxicity; and transfusion reactions due to ABO and other antibodies. CONCLUSION: Several clinically relevant questions remained unresolved, and diagnostic tools were lacking to routinely and reliably predict the clinical consequences of RBC antibodies. Most hemolytic transfusion reactions associated with IVIG were due to ABO antibodies. Reducing the titers of such antibodies in IVIG may lower the frequency of this kind of adverse event. The only way to stop these events is to have no anti-A or anti-B in the IVIG products.


Subject(s)
Autoantibodies/immunology , Erythrocytes/immunology , Hemolysis/immunology , Isoantibodies/immunology , Transfusion Reaction/immunology , Animals , Autoantibodies/adverse effects , Hemagglutinins/immunology , Hemagglutinins/therapeutic use , Hemolysis/drug effects , Humans , Immunoglobulin G/immunology , Immunoglobulin M/immunology , Immunoglobulins, Intravenous/immunology , Immunoglobulins, Intravenous/therapeutic use , Isoantibodies/adverse effects , Transfusion Reaction/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...